Clinical Trial Update: A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the safety and efficacy of an aromatase inhibitor in combination with lapatinib, trastuzumab, or both for hormone receptor-pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Receptor-positive Metastatic Breast Cancer

Drugs mentioned

• Lapatinib (Lapatinib)
• Letrozole (letrozole)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Neoplasms, Breast | Phase 3 | Status: COMPLETED | Results posted: 2019-07-15